Navigation Links
How Early Detection Of Stomach Cancer Is Being Revolutionized

ST. LOUIS, Oct. 25, 2013 /PRNewswire-iReach/ -- Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.


According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.

"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II and possibly enodoscopic examination," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies has been producing  tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."

Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. LeeBio currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.

About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit

Media Contact: Burton Lee, Lee Biosolutions, Inc, 314-968-1091,

News distributed by PR Newswire iReach:

SOURCE Lee Biosolutions, Inc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Study suggests: Blood test can differentiate between benign lung nodules and early stage lung cancer
2. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
3. Early Opportunities to Set the Course for Successful Global Marketing Authorization, New Life Science Webinar Hosted by Xtalks
4. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
5. Early In Vivo Visualization of Retinoblastoma Tumors in Histologic Detail
6. Vince & Associates, Brad Vince Expands Early Phase Gastrointestinal Capabilities
7. JCI early table of contents for Aug. 15, 2013
8. JCI early table of contents for Aug. 8, 2013
9. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
10. RiboMed and Austrian Institute of Technology Partner on Epigenetic Tests for Early Lung Cancer Detection, Sub-typing and Drug Response
11. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment
Post Your Comments:
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):